Showing 20 of 44 recruiting trials for “thomsen-and-becker-disease”
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Efficacy and Safety of Telitacicept in IgAN
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
🏥 Otsuka Pharmaceutical Development & Commercialization, Inc.📍 5 sites📅 Started Nov 2024View details ↗
RecruitingNCT06676007 ↗
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
A Study of Probiotics in IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
RecruitingNCT05434325 ↗
TESTING -ON Post-Trial ObservatioNal Cohort Study
👨⚕️ Hong Zhang, Prof, Peking University Institute of Nephrology📍 58 sites📅 Started Dec 2022View details ↗
RecruitingNCT05234463 ↗
Study of the Link Between Complement Activation and IgA Nephropathy Severity
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
🏥 Otsuka Pharmaceutical Development & Commercialization, Inc.📍 1 site📅 Started Apr 2022View details ↗
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →